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Infectious Port Complications Are More Frequent in Younger
Patients with Hematologic Malignancies than in Solid Tumor
Patients
Abstract
Background: We assessed longevity and complications of totally implantable venous access devices in
oncology patients. Methods: 197 patients received a total of 201 port devices via the subclavian vein for
delivery of chemotherapy between January 1, 2005, and December 31, 2006. We reviewed the patient
charts for port-related complications and risk factors until July 31, 2007. Results:A total of 47,781
catheter days were analyzed (median, 175 days; range, 1-831). Forty-six different complications
occurred (0.96 complications/1,000 catheter days). The only risk factor significantly associated with a
higher complication rate was younger age. Older patients had a lower risk for developing complications
with a risk reduction of 2.4% for each year. There were no differences regarding underlying tumor,
gender, access side, method of placement (subclavian/cephalic vein) or implanting team (thoracic versus
visceral surgery). A trend was seen for shorter port longevity in hematologic patients compared to
oncologic patients (p = 0.059). The former developed significantly more port-associated infections than
solid tumor patients [11/53 cases (21%) versus 2/148 cases (1.4%); p < 0.0001]. Conclusions:
Port-associated infections were mostly observed in younger patients with hematologic neoplasms.
Prospective trials should be performed to evaluate the benefit of a prophylactic antimicrobial lock in
these selected patients.
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0.0001].  Conclusions: Port-associated infections were most-
ly observed in younger patients with hematologic neo-
plasms. Prospective trials should be performed to evaluate 
the benefit of a prophylactic antimicrobial lock in these se-
lected patients.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Totally implantable port systems have been widely 
used in the last two decades for delivery of long-term 
medical therapy like antibiotics, parenteral nutrition or 
anticancer drugs in oncology patients  [1] . They succeed-
ed the subcutaneously tunneled catheter systems like 
Hickman or Groshong lines, which had been developed 
for long-term use in the 1970s  [2] . Implantable port de-
vices have numerous advantages over conventional cen-
tral venous catheters (CVCs). They can be used over long 
periods of time after one-time implantation thus avoid-
ing repeated insertions of a CVC. They can be implanted 
in local anesthesia in an outpatient setting. Patient com-
pliance is excellent since peripheral venipunctures can be 
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 Abstract 
 Background: We assessed longevity and complications of 
totally implantable venous access devices in oncology pa-
tients.  Methods: 197 patients received a total of 201 port de-
vices via the subclavian vein for delivery of chemotherapy 
between January 1, 2005, and December 31, 2006. We re-
viewed the patient charts for port-related complications and 
risk factors until July 31, 2007.  Results:  A total of 47,781 cath-
eter days were analyzed (median, 175 days; range, 1–831). 
Forty-six different complications occurred (0.96 complica-
tions/1,000 catheter days). The only risk factor significantly 
associated with a higher complication rate was younger age. 
Older patients had a lower risk for developing complications 
with a risk reduction of 2.4% for each year. There were no dif-
ferences regarding underlying tumor, gender, access side, 
method of placement (subclavian/cephalic vein) or implant-
ing team (thoracic versus visceral surgery). A trend was seen 
for shorter port longevity in hematologic patients compared 
to oncologic patients (p = 0.059). The former developed sig-
nificantly more port-associated infections than solid tumor 
patients [11/53 cases (21%) versus 2/148 cases (1.4%); p  ! 
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avoided and quality of life is not impaired  [3] . The high 
purchase and insertion costs are redeemed by low main-
tenance costs  [4] .
 Generally, implantation of a port system is considered 
when a medical therapy is planned to exceed 2 months or 
if peripheral vascular access is difficult to achieve.
 Different studies have evaluated the usefulness and re-
liability of totally implantable catheter devices with par-
ticular interest for the most common complications oc-
curring during or after implantation  [5–11] . As a measure 
of quality control at our center, we performed a retrospec-
tive analysis to identify complications in our patients 
with implanted port systems.
 Patients and Methods 
 We performed a retrospective analysis of 197 oncology pa-
tients who received a total of 201 port systems for delivery of che-
motherapy between January 1, 2005, and December 31, 2006. The 
study was approved by the ethics committee, and patients gave 
written informed consent for the scientific analysis of their data. 
A single type of port system (BardPort TM implantable titanium 
device with a self-sealing rubber septum and an open-ended sili-
cone catheter; Bard Access Systems, Salt Lake City, Utah, USA) 
was used. Patients who received intra-abdominal port systems for 
regional hepatic chemotherapy or other types of central venous 
access devices like Shaldon’s catheters for stem cell apheresis were 
excluded from the present study. The ports were placed by the 
team of either the department of thoracic surgery (n = 153) or of 
the department of visceral and transplantation surgery (n = 48) 
in the operating room under general or local anesthesia. Peri-in-
sertional antibiotics were given in selected patients only. In 59 of 
the 201 cases (29%) either   -lactam antibiotics or quinolones were 
applied as prophylaxis. The port system was implanted in the 
right (n = 160) or left (n = 41) pectoralis fascia after formation of 
a subcutaneous pocket in the infraclavicular area. Two techniques 
were used for venous access: direct puncture of the subclavian 
vein (n = 62; 31%) or surgical cut-down to the cephalic vein (n = 
139; 69%), depending on the patient’s anatomy. When the surgeon 
could not access the subclavian vein by advancing the guide wire 
through the cephalic vein, the procedure was changed to a direct 
puncture of the subclavian vein. The correct catheter position in 
the superior vena cava was checked perioperatively by fluoros-
copy and postoperatively by chest radiography. Immediate use of 
the system was permitted after radiological control of the catheter 
position. Patients were treated in an outpatient and/or inpatient 
setting by specially trained oncology nursing staff. The same 
team took care of the ports according to the recommendations of 
the manufacturer. Lock with heparin solution was performed af-
ter every access and every 4–12 weeks if the system was not in use. 
Patients did not routinely receive oral anticoagulants or heparin 
for prevention of thrombosis.
 Ninety (47%) patients were female and 107 (53%) male. The 
median patient age was 58 years (range, 18–86).
 In 148 cases, the underlying disease was a solid tumor, and in 
53 cases a hematologic malignancy. Underlying diagnoses are 
shown in  figure 1 . We analyzed the electronic patient charts of 
our digital clinical information system (KISIM version 4.813, 
CISTEC AG, Zurich, Switzerland) and the patient charts of the 
oncology department to determine the incidence of port-related 
complications up to July 31, 2007, and evaluated possible risk fac-
tors. An event leading to censoring of the data was defined as the 
occurrence of either a complication, death of any cause, end of 
analysis or port removal. All complications that occurred in the 
observation period were considered for analysis if they were pre-
sumably associated with the port system. Early postoperative 
complications like pneumothorax or hematoma were also includ-
ed. Deep venous thrombosis was defined as occlusion of the large 
veins as seen with Doppler ultrasound, phlebography or CT scan. 
Occlusions of the catheter by a fibrin sleeve without radiographic 
proof of thrombosis were defined as thrombotic complication 
only if flushing with urokinase did not result in patency of the 
system. Infections of the catheter or needle insertion site, pocket 
infections and catheter-related blood stream infections (CRBSI) 
were defined as port-associated infections. Fever of unknown or-
igin (FUO) was defined as port related if persistent symptoms 
under antibiotic therapy necessitated port removal.
 Neutropenia was defined as less than 1,000 neutrophils per 
cubic millimeter of blood.
 Statistical calculations were performed with the Statistical 
Analysis Software SPSS 13 for Mac OS X (SPSS Inc., Chicago, Ill., 
USA). The log rank test was used to compare two groups in regard 
to the time to port-related complications. In order to determine 
risk factors for complications, a Cox regression analysis was per-
formed. The significance of an association between two variables 
was assessed by Fisher’s exact test or Student’s t test. p values 
 ! 0.05 were considered statistically significant.
 Results 
 One hundred and ninety-seven patients received a to-
tal of 201 port systems. A total of 47,781 catheter days 
were documented (median, 175 days; range, 1–831). For-
Lower GI tract: 33 (16.4%)
Upper GI tract: 18 (9%)
Liver: 3 (1.5%)
Hodgkin: 8 (4%)
Head/neck: 9 (4.5%)
Urogenital: 11 (5.5%)
ALL: 6 (3%)
Lung: 26 (12.9%)
Myeloma: 12 (6%)
Breast: 17 (8.5%)
NHL: 27 (13.4%)
Other: 10 (5%)
Sarcoma: 4 (2%)
Pancreas: 17 (8.5%)
 Fig. 1. Primary diagnoses in the patient population. ALL = Acute 
lymphoblastic leukemia; GI = gastrointestinal; NHL = non-Hodg-
kin’s lymphoma. 
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ty-six (23%) complications occurred until the cut-off date 
of July 31, 2007 (0.96 complications/1,000 port days). The 
complications and actions taken are listed in  table 1 . The 
most common complications were thrombosis (n = 12; 
6%; 0.25 complications/1,000 port days), port-associated 
infection (n = 13; 6.5%; 0.27) and catheter malposition
(n = 9; 4.5%; 0.19). Other complications were hematoma 
(n = 5; 2.5%; 0.1), pneumothorax (n = 4; 2%; 0.08), arte-
rial puncture (n = 1; 0.5%; 0.02), FUO (n = 1; 0.5%; 0.02) 
and unsuccessful port placement (n = 1; 0.5%; 0.02). Nine-
teen complications required port removal and one im-
plantation failed (n = 20; 10%; 0.42). In 22 of the 46 cases 
with documented complications, port function was pre-
served and the system remained in use. Four port systems 
remained in situ without further use. After detection of 
a deep venous thrombosis, the port system remained 
functional in 7 of 12 cases, two ports had to be removed, 
and three remained in situ without further use. Port-as-
sociated infections consisted of four catheter or port nee-
dle insertion site infections, two pocket infections and 
seven CRBSI. Infections and one case of FUO resulted in 
removal of 12 of the 14 devices. In two cases of insertion 
site infection, the systems could be rescued by systemic 
antibiotics and vancomycin lock. Identified pathogens 
were coagulase-negative  Staphylococcus (n = 4),  Staphylo-
coccus aureus (n = 2),  Escherichia coli (n = 1),  Pseudomo-
nas aeruginosa (n = 1) and  Corynebacterium amycolatum 
(n = 1). The underlying diagnoses in patients with infec-
tious complications were aggressive non-Hodgkin’s lym-
phomas (n = 6), acute lymphocytic leukemia (n = 2), 
Hodgkin’s lymphoma (n = 2), multiple myeloma (n = 1), 
nonseminomatous germ cell tumor (n = 1), small cell lung 
cancer (n = 1) and colorectal cancer (n = 1). These patients 
received the following treatments: Hyper-CVAD (cyclo-
phosphamide, vincristine, doxorubicin, dexamethasone, 
cytarabine, methotrexate) with (n = 1) or without (n = 2) 
rituximab, EPOCH (etoposide, vincristine, doxorubicin, 
cyclophosphamide, prednisone; n = 2), ICE (ifosfamide, 
carboplatin, etoposide) with rituximab (n = 1), CHOP 
(cyclophosphamide, doxorubicin, vincristine, predni-
sone) with rituximab (n = 1), cytarabine/etoposide (n = 
1), Mini-BEAM (carmustine, etoposide, cytarabine, mel-
phalan; n = 1), docetaxel/ifosfamide (n = 1), topotecan 
monotherapy (n = 1) and dose-intense chemotherapy (cy-
Table 1. Complications
All cases
(n = 201)
Events/1,000
port days
Solid
(n = 148)
Hem
(n = 53)
Actions taken
Unsuccessful placement 1 (0.5) 0.02 0 1 (2) –
Hematoma 5 (2.5) 0.1 3 (2) 2 (4) hematoma excision (n = 2)
port functional, left in situ (n = 5)
Arterial puncture 1 (0.5) 0.02 1 (1) 0 port removal
Pneumothorax 4 (2) 0.08 4 (3) 0 chest tube (n = 3)
port functional, left in situ (n = 4)
Port-associated infection 13 (6.5) 0.27 2 (1) 11 (21) port removal (n = 11)
antibiotic lock, rescue (n = 1)
systemic antibiotics, rescue (n = 1)
Port-associated bacteremia 1 (0.5) 0.02 1 (1) 0 port removal
Deep venous thrombosis 12 (6) 0.25 9 (6) 3 (6) port removal (n = 2)
port nonfunctional, left in situ,
anticoagulation (n = 3)
port functional, left in situ,
anticoagulation (n = 7)
Malposition 9 (4.5) 0.19 6 (4) 3 (6) port removal (n = 4)
port not used, left in situ (n = 1)
port functional, left in situ (n = 2)
port revision (n = 2)
Total 46 (23) 0.96 26 (18) 20 (38) –
Figures in parentheses indicate percentages. Solid = Patients with solid tumors; Hem = patients with hematologic neoplasms.
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clophosphamide/total body irradiation and high-dose 
melphalan, respectively) with autologous stem cell trans-
plantation (n = 2). At the time of infection, 6 patients were 
neutropenic and 4 patients had just recovered from neu-
tropenia. The median duration of neutropenia in patients 
with an infection was 5 days (range, 0–25 days).
 The median port survival time was not reached at the 
end of the study, exceeding 831 days. The risk of an event 
was highest in the first month due to inclusion of periop-
erative and early postoperative complications in the anal-
ysis and leveled off thereafter ( fig. 2 a). The only signifi-
cant risk factor associated with a higher complication rate 
in the Cox regression analysis was younger age (multipli-
cative effect on the hazard ratio per year, 0.976; 95% CI, 
0.957–0.996; p = 0.019). Older patients had a lower risk for 
developing port complications with a calculated risk re-
duction of 2.4% for each year. While the median age of 
the whole patient population was 58 years (range, 18–86), 
patients with port-related infections had a median age of 
45 years (range, 18–74), whereas patients with thrombo-
ses were 52 years (range, 22–65) and patients with cath-
eter malpositions 64 years (range, 31–74) old.
 There were no significant differences regarding the 
underlying tumor, gender, placement side (left versus 
right), access method (subclavian versus cephalic vein) or 
implanting team (from the department of thoracic sur-
gery versus the department of visceral surgery). When 
the patients were divided into two groups, i.e. as having 
hematologic neoplasms or solid tumors, a trend was seen 
for shorter event-free port longevity in patients with he-
matologic malignancies compared with solid tumor pa-
tients (p = 0.059 in the log rank test). The hazard ratio for 
an event was 0.572 in favor of solid tumor patients (95% 
CI, 0.318–1.03; p = 0.063;  fig. 2 b). Patients with hemato-
logic malignancies were significantly younger than solid 
tumor patients (mean 47.3  8 15.2 years versus 58.6  8 
12.2 years; p  ! 0.001 in the Student’s t test; 95% CI for the 
difference in age, 7.17–15.39 years;  fig. 3 ).
 When analyzed in reference to port-associated infec-
tions, patients with hematologic diseases developed sig-
nificantly more complications compared to patients who 
had solid tumors [11/53 cases (21%) versus 2/148 cases 
(1.4%); p  ! 0.0001 in the Fisher’s exact test].
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 Fig. 3. Boxplot showing the difference in age between patients 
with solid tumors (solid) and patients with hematologic malig-
nancies (nonsolid). 
 Fig. 2.  a Kaplan-Meier analysis of the event-free port longevity 
measured from the day of placement.  b Event-free port longevity 
in patients with solid tumors compared to patients with hemato-
logic neoplasms. Marks represent censored data, i.e. day of port 
removal, patient’s death, end of study period or occurrence of 
complication. Perioperative complications (pneumothorax and 
hematoma) were included in the analysis.  
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 Discussion 
 Totally implantable venous access devices have proved 
to be less susceptible to complications than tunneled 
catheter systems  [10, 12, 13] . The reported event rate 
ranged from 0.45 to 1.16 events/1,000 port days  [5–11] . 
Our study showed comparable results with 0.96 overall 
events/1,000 port days. The main complications observed 
were port-associated thrombosis (0.25 events), port-as-
sociated infection (0.27 events) and catheter malposition 
(0.19 events). A comparison of the published literature 
and our data is presented in  table 2 showing similar re-
sults. Rare complications were puncture of the artery, 
port placement failure and hematoma in the early post-
operative period. Four cases of pneumothorax occurred 
after puncture of the subclavian vein. This complication 
could be avoided by using the surgical cut-down tech-
nique to the cephalic vein. An option to reduce the rate 
of complications and to improve the success rate with the 
percutaneous approach may be the use of two-dimen-
sional ultrasound for guidance of the cannulation  [14, 
15] .
 Six percent of our patients developed catheter-related 
thrombosis. No predisposing risk factors were observed 
in our study. Other trials have identified significant vari-
ables for the development of arm vein thrombosis: cath-
eter tip position, side of catheter insertion (right versus 
left), platelet count, female gender and underlying lung 
cancer  [11, 16–18] . One study tested treatment with low 
molecular weight heparin (LMH) for prevention of cath-
eter-related thrombosis after port placement and found a 
significant reduction in the incidence of thrombotic com-
plications. However, this study had a very high thrombo-
sis rate in the untreated arm (62% of the patients)  [19] . 
High rates of thrombotic complications were also ob-
served in two other trials with indwelling CVCs using 
LMH or low dose warfarin for prophylaxis  [20, 21] . The 
main reason for these high rates reported may be the sys-
tematic search for thromboses by using phlebography in 
all study patients. We performed phlebography only in 
case of suspected thrombosis based on clinical symp-
toms. But even if only the symptomatic patients who re-
ceived a prophylaxis were considered for comparison, we 
found a low rate of thrombosis without any anticoagula-
tion (6%). In more recent trials, the thrombosis rate was 
in the range of our study, ranging from 3.5 to 18%, and 
no significant reduction of the thrombosis incidence was 
seen with LMH or warfarin administration compared 
with placebo  [22–25] . Apparently, thorough system care 
by flushing the port system at regular intervals with a 
heparin solution may be sufficient for maintaining these 
low rates of thrombotic complications. Therefore, the use 
of LMH or oral anticoagulants for prevention of port-re-
lated thrombosis is not generally recommended.
 Twenty-nine percent of the patients received peri-in-
sertional antibiotics. In our series, only 4 of the docu-
mented 14 infectious complications occurred within the 
first month with the earliest occurring at day 15 after im-
plantation. One of these 4 patients had received prophy-
lactic antibiotic treatment. We suggest that the applied 
prophylaxis with   -lactam antibiotics or quinolones did 
not have a relevant impact on the infection rate.
 Patients with hematologic malignancies developed 
significantly more infectious complications than patients 
with solid tumors. Coagulase-negative  Staphylococcus 
was the main pathogen isolated. This observation has 
been made in previous studies as well  [11] . The difference 
in the incidence of infections may be attributable to more 
intense chemotherapy, resulting in prolonged neutrope-
nia, and also to a direct impairment of the immune sys-
tem by the disease itself. Lack of immunocompetence is 
a main risk factor for infections, as seen in patients with 
Table 2. Literature comparison
Study Cases Days in
situ
Events/
1,000 port days
Infections/
1,000 port days
Thrombosis/
1,000 port days
Biffi et al., 1997 [5] 178 180 0.65 0.16 0.06
Brown et al., 1997 [6] 158 270 0.62 0.35 0.14
Kock et al., 1998 [7] 1,500 284 0.45 0.17 0.11
Lyon et al., 1999 [8] 205 169 1.16 0.21 0.27
Wolosker et al., 2004 [9] 519 353 0.5 0.23 0.07
Caers et al., 2005 [11] 448 366 0.85 0.19 0.35
Present study 201 238 0.96 0.27 0.25
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HIV, who develop significantly more port infections than 
cancer patients (1.5 vs. 0.96 infections/1,000 port days) 
 [26] . The pathogens described in the literature are pre-
dominantly Gram-positive cocci with coagulase-nega-
tive  Staphylococcus accounting for 50% of all cases  [13, 
26–28] . Our treatment usually comprised the removal of 
the colonized port system. However, while pocket infec-
tions are always an indication for device removal, a com-
bined local and systemic antibiotic therapy may be con-
sidered to preserve the port in CRBSI if risk factors for 
treatment failure like heart valve prosthesis or concur-
rent thrombosis are absent, according to guidelines for 
the treatment of catheter-related infections  [29, 30] . The 
strategy is also dependent on the isolated pathogen. Re-
moval is always necessary in infections with  S. aureus 
 and  Candida spp., while a preservation of the system may 
be successful with coagulase-negative  Staphylococcus , 
 Corynebacterium jeikeium and  P. aeruginosa  [31] . By
applying antibiotics intraluminally in high concentra-
tions – the so called antibiotic lock technique – 80% of 
the colonized catheter lines may be rescued  [32, 33] . The 
antibiotic-lock technique was superior to systemic treat-
ment alone with regard to preservation of infected ports 
in immunocompromised patients  [34, 35] . Numerous an-
tibiotics were tested for the lock technique, but the agent 
most extensively studied is vancomycin  [36] . The use of 
vancomycin has various advantages: it targets Gram-pos-
itive pathogens, it is compatible with heparin in effective 
concentrations, and it remains chemically stable and bio-
logically active for at least 25 days in vivo  [37–39] . Since 
 hematologic patients are at high risk for developing in-
fectious complications, prophylaxis with a vancomycin-
heparin lock was studied to reduce the incidence of port-
associated infections. A prophylactic vancomycin-hepa-
rin lock was tested in pediatric populations and proved 
effective in reducing CRBSI  [40, 41] . In one study of 117 
adult hematology patients, local application of vancomy-
cin and heparin led to significantly less colonization of 
the catheter system with Gram-positive bacteria and also 
significantly less bacteremias  [42] . Despite good results 
in a few prospective trials with this approach, the wide-
spread use of a vancomycin-heparin lock for prevention 
of CRBSI is not generally recommended because of con-
cerns regarding the emergence of vancomycin-resistant 
pathogens  [31, 43] . As of today, the appearance of antibi-
otic resistance has not been described after a vancomycin 
lock. This may be related to the fact that the solution does 
not reach the circulation if applied properly. We think 
that prophylaxis with a vancomycin-heparin lock could 
be considered an option in selected hematologic patients 
who are at high risk for developing CRBSI. Another 
promising approach to circumvent this problem may be 
the prophylactic application of ethylenediaminetetraace-
tic acid (EDTA), a chelating, nonantibiotic agent to re-
main in the port system. More recent studies have dem-
onstrated its efficacy in reducing CRBSI due to its anti-
microbial properties against various pathogens, either 
alone or combined with other agents  [44, 45] . In addition, 
EDTA prevents coagulation by binding calcium and is 
therefore an adequate agent to preserve patency of the 
catheter system.
 The only patient-related risk factors for the develop-
ment of port-related complications identified in the Cox 
regression analysis were younger age and underlying he-
matologic malignancy. These two factors are related to 
each other, since patients with hematologic neoplasms 
were significantly younger than solid tumor patients 
(mean, 47.3  8 15.2 years vs. 58.6  8 12.2 years). Here, in-
fections were the main type of complication. This is most 
likely attributable to the more intense chemotherapy 
causing prolonged neutropenia. We observed that 10 of 
the 14 patients who developed infectious complications 
were neutropenic or had recovered from neutropenia 
shortly before the complication occurred. A direct cor-
relation between the degree of neutropenia and infec-
tious complications was demonstrated 40 years ago  [46] . 
The risk for a patient to develop catheter-related infec-
tions is elevated during neutropenic periods compared to 
nonneutropenic periods  [47, 48] . Patients who receive 
dose-intensive chemotherapy might therefore be treated 
with granulocyte colony-stimulating factor to reduce the 
length of neutropenia and the incidence of infectious 
complications  [49] .
 In conclusion, in our series of 201 port placements, 
thrombotic complications were observed rarely. Patients 
with hematologic malignancies were younger and had a 
higher risk of developing port-associated infections than 
solid tumor patients, resulting in a trend to shorter event-
free port longevity.
 Therefore, we suggest that trials be performed to eval-
uate the benefit of a catheter lock with antimicrobial 
agents at regular intervals in younger patients with hema-
tologic malignancies.
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